11 β-Hydroxysteroid dehydrogenase type II inhibition causes cerebrovascular remodeling and increases infarct size after cerebral ischemia

Endocrinology

Volumn 150, Issue 2, 2009, Pages 713-719

  Osmond, Jessica M ^a   Dorrance, Anne M ^b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBENOXOLONE; OXPRENOATE POTASSIUM; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; ENZYME INHIBITOR; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BRAIN DAMAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TELEMETRY; ANIMAL; BRAIN CIRCULATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; MIDDLE CEREBRAL ARTERY; MUSCLE DEVELOPMENT; MUSCLE TONE; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ANIMALS; BRAIN ISCHEMIA; CARBENOXOLONE; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; ENZYME INHIBITORS; MALE; MIDDLE CEREBRAL ARTERY; MUSCLE DEVELOPMENT; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; VASOCONSTRICTION;

EID: 59649095837     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0808     Document Type: Article

References (36)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
2. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
3. Rigsby CS, Pollock DM, Dorrance AM 2007 Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats. Microvasc Res 73:198-205
4. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM 1987 Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
5. Krozowski ZS, Funder JW 1983 Renal mineralocorticoid receptors and hippocampal corticosterone-binding species have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80:6056-6060
6. Funder JW, Pearce PT, Smith R, Smith AI 1988 Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
7. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR 1987 Mineralocorticoid activity of liquorice: 11-β-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2:821-824
8. Kuhnle U, Lewicka S, Fuller PJ 2004 Endocrine disorders of sodium regulation. Role of adrenal steroids in genetic defects causing sodium loss or sodium retention. Horm Res 61:68-83
9. Lifton RP, Gharavi AG, Geller DS 2001 Molecular mechanisms of human hypertension. Cell 104:545-556
10. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C 1988 Localisation of 11 β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
11. New MI, Levine LS, Biglieri EG, Pareira J, Ulick S 1977 Evidence for an unidentified steroid in a child with apparent mineralocorticoid hypertension. J Clin Endocrinol Metab 44:924-933
12. Stewart PM, Corrie JE, Shackleton CH, Edwards CR 1988 Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 82:340-349
13. Mantero F, Palermo M, Petrelli MD, Tedde R, Stewart PM, Shackleton CH 1996 Apparent mineralocorticoid excess: type I and type II. Steroids 61:193-196
14. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS 1994 Cloning and tissue distribution of the human 11 β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17
15. Rusvai E, Naray-Fejes-Toth A 1993 A new isoform of 11 β-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 268:10717-10720
16. Funder JW 2005 RALES, EPHESUS and redox. J Steroid Biochem Mol Biol 93:121-125
17. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472
18. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121-1125
19. Coyle P 1989 Altered cerebral collaterals and protection from infarction. In: Hartmann A, Kuschinsky W, eds. Cerebral ischemia and calcium. Heidelberg, Germany: Springer-Verlag; 69-78
20. Coyle P, Heistad DD 1991 Development of collaterals in the cerebral circulation. Blood Vessels 28:183-189
21. Baumbach GL, Heistad DD 1989 Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13:968-972
22. Heistad DD, Mayhan WG, Coyle P, Baumbach GL 1990 Impaired dilatation of cerebral arterioles in chronic hypertension. Blood Vessels 27:258-262
23. Dorrance AM, Rupp NC, Nogueira EF 2006 Mineralocorticoid receptor activation causes cerebral vessel remodeling and exacerbates the damage caused by cerebral ischemia. Hypertension 47:590-595
24. Dorrance AM, Osborn HL, Grekin R, Webb RC 2001 Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats. Am J Physiol Regul Integr Comp Physiol 281:R944-R950
25. Longa EZ, Weinstein PR, Carlson S, Cummins R 1989 Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20:84-91
26. Dorrance AM, Pollock DM, Romanko OP, Stepp DW 2007 A high-potassium diet reduces infarct size and improves vascular structure in hypertensive rats. Am J Physiol Regul Integr Comp Physiol 292:R415-R422
27. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR 1990 A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 10:290-293
28. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG 1998 Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31:445-450
29. McMahon GT, Dluhy RG 2004 Glucocorticoid-remediable aldosteronism. Cardiol Rev 12:44-48
30. Watts SW, Gilbert L, Webb RC 1995 5-Hydroxytryptamine2B receptor mediates contraction in the mesenteric artery of mineralocorticoid hypertensive rats. Hypertension 26(6 Pt 2):1056-1059
31. Banes AK, Watts SW 2002 Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension 39(2 Pt 2):394-398
32. Alzamora R, Michea L, Marusic ET 2000 Role of 11 β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35:1099-1104
33. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR 2003 11 β-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 42:580-587
34. Gomez-Sanchez EP, Gomez-Sanchez CE 1992 Central hypertensinogenic effects of glycyrrhizicacid and carbenoxolone. Am J Physiol 263(6Pt1):E1125- E1130
35. Leshchenko Y, Likhodii S, Yue W, Burnham WM, Perez Velazquez JL 2006 Carbenoxolone does not cross the blood brain barrier: an HPLC study. BMC Neurosci 7:3
36. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T 1995 Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan. J Endocrinol Invest 18:370-373